Serum Concentrations of Vascular Endothelial Growth Factor in Advanced Non-Small Cell Lung Cancer

Trapé, Jaume; Buxó, J; Olaguer, Joaquim Pérez de

doi:10.1373/49.3.523

Cited by 12 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, lung cancer patients presented higher levels of VEGF in serum than did control individuals, as observed in other studies (17)(18)(19)(20)(21)(22)(23)(24)(25). Studies like those reported by Trape (19) and Hasegawa et al (21) that included patients with nontumor pulmonary diseases, such as asthma or chronic obstructive pulmonary disease (COPD), have also revealed that the VEGF levels in serum are lower than those of lung cancer patients.…”

Section: Discussionsupporting

confidence: 89%

“…Studies like those reported by Trape (19) and Hasegawa et al (21) that included patients with nontumor pulmonary diseases, such as asthma or chronic obstructive pulmonary disease (COPD), have also revealed that the VEGF levels in serum are lower than those of lung cancer patients. Wasada et al (26) indicate that the tissue damage produced by tobacco in smokers does not increase circulating VEGF concentrations.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 87%

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Similarly, several authors have also shown VEGF not to independently influence survival of NSCLC patients [47,48,49]. …”

Section: Discussionmentioning

confidence: 87%

Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis

Kamińska¹,

Kowalska²,

Kotowicz³

et al. 2006

Oncology

112

View full text Add to dashboard Cite

Objectives: Cytokines are potential new serum markers, especially desirable for malignancies with poor prognosis like non-small cell lung cancer (NSCLC). Methods: Cytokines, tumor necrosis factor α (TNFα), interleukin (IL)-6 and IL-8, soluble TNF (sTNF) RI, sTNF RII, soluble IL-2 receptor-α, IL-1 receptor antagonist (IL-1ra), IL-10, vascular endothelial growth factor, basic fibroblast growth factor, and macrophage (M-CSF) and granulocyte colony-stimulating factor, as well as tumor markers – carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and CYFRA 21.1 – were assessed in the sera of 103 untreated NSCLC patients, and these cytokines and tumor markers were refered to clinical parameters of the disease and to the overall survival of patients evaluated during a 6-year follow-up. Results: Most of the factors analyzed were found to be elevated in the sera of NSCLC patients, and increases in IL-6, IL-8 and sTNF RI were noted in the greatest proportion of stage I patients. Most cytokine/cytokine receptor levels revealed higher sensitivity than the standard tumor markers; IL-6 and IL-1ra levels were significantly different in patients with squamous cell versus adenocarcinoma; IL-6 and IL-10 were related to the tumor size, while IL-6 and M-CSF levels significantly increased with disease progression. A significant prognostic value of pretreatment serum M-CSF and CEA levels in NSCLC patients has been shown, but only M-CSF proved to be an independent prognostic factor. Conclusions: Increased pretreatment serum M-CSF level is a significant independent predictor of poor survival in patients with NSCLC.

show abstract

“…According to our literature search, 16 published studies have reported on the prognostic impact of elevated levels of VEGF in blood (Table 4). Of these, 10 dealt with the prognostic impact of circulating VEGF on survival [112,[145][146][147][148][149][150][151][152][153]. Four of these studies revealed a significantly inverse association between circulating levels and survival, while the study by Trapé et al [150] tended towards a poor survival (9 months versus 13.5 months) at high VEGF levels.…”

Section: Vegf In Serum or Plasmamentioning

confidence: 99%

Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood

2006

View full text Add to dashboard Cite

Serum Concentrations of Vascular Endothelial Growth Factor in Advanced Non-Small Cell Lung Cancer

Cited by 12 publications

References 3 publications

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis

Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood

Contact Info

Product

Resources

About